Allergy Therapeutics (AGY) — Strategic Asset Allocation Index
Allergy Therapeutics (AGY) has a Strategic Asset Allocation Index of 1160.6% as of June 2023. Strategic assets (PP&E of GBX23.98 Million plus long-term investments of GBX-) total GBX23.98 Million, measured against net assets of GBX2.07 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Allergy Therapeutics Strategic Asset Allocation Index (2003–2023)
This chart shows how Allergy Therapeutics's Strategic Asset Allocation Index has evolved across 19 annual periods from 2003 to 2023. As of June 2023, the index stands at 1160.6%, representing strategic assets of GBX23.98 Million against net assets of GBX2.07 Million GBX. Explore cash flow conversion of Allergy Therapeutics to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Allergy Therapeutics (2003–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for Allergy Therapeutics from 2003 to 2023, covering 19 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Allergy Therapeutics stock valuation.
| Year | SAAI | Strategic Assets (GBX) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 1160.6% | GBX23.98 Million | GBX23.98 Million | GBX- | GBX2.07 Million | ▲ +1107.1 pp |
| 2022 | 53.5% | GBX20.19 Million | GBX20.19 Million | GBX- | GBX37.77 Million | ▲ +12.8 pp |
| 2021 | 40.6% | GBX19.72 Million | GBX19.72 Million | GBX- | GBX48.53 Million | ▼ -6.0 pp |
| 2020 | 46.6% | GBX20.42 Million | GBX20.42 Million | GBX- | GBX43.78 Million | ▲ +16.1 pp |
| 2019 | 30.6% | GBX11.48 Million | GBX11.48 Million | GBX- | GBX37.56 Million | ▼ -13.3 pp |
| 2018 | 43.8% | GBX10.10 Million | GBX10.10 Million | GBX- | GBX23.03 Million | ▲ +11.5 pp |
| 2017 | 32.3% | GBX9.67 Million | GBX9.67 Million | GBX- | GBX29.96 Million | ▲ +0.4 pp |
| 2016 | 31.9% | GBX9.67 Million | GBX9.67 Million | GBX- | GBX30.32 Million | ▲ +6.5 pp |
| 2015 | 25.4% | GBX8.75 Million | GBX8.75 Million | GBX- | GBX34.47 Million | ▼ -21.2 pp |
| 2014 | 46.6% | GBX7.03 Million | GBX7.03 Million | GBX- | GBX15.07 Million | ▼ -3.4 pp |
| 2013 | 50.0% | GBX7.34 Million | GBX7.34 Million | GBX- | GBX14.67 Million | ▼ -1.8 pp |
| 2012 | 51.8% | GBX7.55 Million | GBX7.55 Million | GBX- | GBX14.59 Million | ▼ -360.1 pp |
| 2011 | 411.8% | GBX8.81 Million | GBX8.81 Million | GBX- | GBX2.14 Million | ▲ +181.8 pp |
| 2010 | 230.0% | GBX8.94 Million | GBX8.94 Million | GBX- | GBX3.89 Million | ▲ +161.0 pp |
| 2007 | 69.0% | GBX5.93 Million | GBX5.93 Million | GBX- | GBX8.60 Million | ▲ +57.9 pp |
| 2006 | 11.1% | GBX3.64 Million | GBX3.64 Million | GBX- | GBX32.70 Million | ▲ +0.6 pp |
| 2005 | 10.5% | GBX2.11 Million | GBX2.11 Million | GBX- | GBX20.08 Million | ▼ -12.8 pp |
| 2004 | 23.3% | GBX1.65 Million | GBX1.65 Million | GBX- | GBX7.08 Million | ▲ +1.3 pp |
| 2003 | 22.0% | GBX1.22 Million | GBX1.22 Million | GBX- | GBX5.55 Million | — |